Through the examination of the relationship between the expression of NCAPG2 and several clinical factors, such as tumor staging and the infiltration of immune cells, we aim to provide insights into the potential of NCAPG2 as a diagnostic marker and its implications in tumor immunity.This research enhances the comprehension of the pathophysiology associated with CHOL and underscores the importance of NCAPG2 within the realm of cancer immunotherapy. This evidence concerns the gene NCAPG2 and cancer.